Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Other Accumulated Expenses data on record, last reported at $105.0 million in Q2 2025.

  • For Q2 2025, Other Accumulated Expenses changed N/A year-over-year to $105.0 million; the TTM value through Jun 2025 reached $105.0 million, changed N/A, while the annual FY2024 figure was $99.0 million, 147.5% up from the prior year.
  • Other Accumulated Expenses reached $105.0 million in Q2 2025 per INDV's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $105.0 million in Q2 2025 and bottomed at $3.0 million in Q1 2025.
  • Average Other Accumulated Expenses over 3 years is $61.8 million, with a median of $69.5 million recorded in 2023.
  • The widest YoY moves for Other Accumulated Expenses: up 147.5% in 2024, down 147.5% in 2024.
  • A 3-year view of Other Accumulated Expenses shows it stood at $40.0 million in 2023, then surged by 147.5% to $99.0 million in 2024, then grew by 6.06% to $105.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $105.0 million in Q2 2025, $3.0 million in Q1 2025, and $99.0 million in Q4 2024.